Adapsyn Bioscience Inc., a biotechnology company focused on the discovery and development of novel medicines derived from evolved small molecule natural products, announced that it has completed a round of financing that was co-funded by Pfizer R&D Innovate and Genesys Capital. In addition, the company has announced a research collaboration with Pfizer Inc.
The Adapsyn platform combines genomic and metabolomic data with AI and machine-learning to identify new ways to develop drugs.
Under the terms of the research agreement, Adapsyn will use their proprietary platform technologies to identify and test previously undiscovered natural products from Pfizer’s collection of microbial strains.
In addition to an upfront payment, should Pfizer advance any potential compounds identified through the collaboration, Adapsyn is entitled to potential payments of up to $162 million, as well as royalties on potential future sales.
Locate at McMaster Innovation Park in Hamilton, Ontario, Adapsyn was set up in 2016 to build on work by Founder and Chief Scientific Officer Dr. Nathan Magarvey.